ES2054878T3 - Expresion de la proapolipoproteina a-i humana. - Google Patents

Expresion de la proapolipoproteina a-i humana.

Info

Publication number
ES2054878T3
ES2054878T3 ES88870095T ES88870095T ES2054878T3 ES 2054878 T3 ES2054878 T3 ES 2054878T3 ES 88870095 T ES88870095 T ES 88870095T ES 88870095 T ES88870095 T ES 88870095T ES 2054878 T3 ES2054878 T3 ES 2054878T3
Authority
ES
Spain
Prior art keywords
expression
human
coding sequence
dna sequences
proapolipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88870095T
Other languages
English (en)
Inventor
Alex Bollen
Jean Gobert
Ernst Wulfert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2054878T3 publication Critical patent/ES2054878T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA SECUENCIAS DE ADN RECOMBINANTES QUE COMPRENDEN UNA SECUENCIA QUE CODIFICA PARA PROAPOLIPROTEINA A-1 HUMANA EN LA QUE UNA PARTE DE LA SECUENCIA CODIFICANTE NATURAL HA SIDO REEMPLAZADA POR UN FRAGMENTO DE ADN QUE CODIFICA PARA LOS MISMOS AMINOACIDOS PERO QUE CONSISTE EN UNA SECUENCIA DE NUCLEOTIDOS DIFERENTE DE MANERA QUE REDUZCA O PREVENGA LA FORMACION DE ESTRUCTURAS EN ALFILER, VECTORES DE CLONADO Y EXPRESION CONTENIENDO ESTAS SECUENCIAS DE ADN, CULTIVOS DE CELULAS O MICROORGANISMOS TRANSFORMADOS CON ESTOS VECTORES DE EXPRESION Y PROCEDIMIENTO QUE LOS UTILIZAN PARA LA PRODUCCION DE PROAPOLIPROTEINA A-1.
ES88870095T 1987-05-28 1988-05-24 Expresion de la proapolipoproteina a-i humana. Expired - Lifetime ES2054878T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (1)

Publication Number Publication Date
ES2054878T3 true ES2054878T3 (es) 1994-08-16

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88870095T Expired - Lifetime ES2054878T3 (es) 1987-05-28 1988-05-24 Expresion de la proapolipoproteina a-i humana.

Country Status (33)

Country Link
US (1) US5059528A (es)
EP (1) EP0293357B1 (es)
JP (1) JP2634193B2 (es)
KR (1) KR970000808B1 (es)
CN (1) CN1031892C (es)
AT (1) ATE89006T1 (es)
AU (1) AU615654B2 (es)
CA (1) CA1323851C (es)
CY (1) CY1809A (es)
CZ (1) CZ283648B6 (es)
DD (1) DD291093A5 (es)
DE (1) DE3880739T2 (es)
DK (1) DK175686B1 (es)
EG (1) EG19101A (es)
ES (1) ES2054878T3 (es)
FI (1) FI100056B (es)
GB (1) GB8712540D0 (es)
HK (1) HK137794A (es)
HU (1) HU204562B (es)
IE (1) IE62422B1 (es)
IL (1) IL86480A (es)
LT (1) LT3600B (es)
LV (1) LV5288A3 (es)
NO (1) NO179253C (es)
NZ (1) NZ224808A (es)
PL (1) PL158064B1 (es)
PT (1) PT87562B (es)
RU (1) RU2009198C1 (es)
SG (1) SG131594G (es)
SK (1) SK279166B6 (es)
SU (1) SU1834904A3 (es)
UA (1) UA19765A (es)
ZA (1) ZA883824B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
EP0345155B1 (en) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Process for producing natural human apolipoprotein e-like proteins
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
EP0785273A1 (en) * 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
EP0559795B1 (en) * 1990-11-30 1995-12-27 Monoclonetics International, Inc. Methods for the diagnosis of chronic lower back and cervical pain
GB9508618D0 (en) * 1995-04-28 1995-06-14 Applied Research Systems Therapeutic protein
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
WO2002048333A2 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
JP2009505652A (ja) * 2005-08-26 2009-02-12 セレニス セラピューティクス ホールディング エスア 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
CA2739464C (en) * 2008-10-03 2020-03-31 Curna, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP4241767B1 (en) 2008-11-10 2024-10-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG176553A1 (en) 2009-05-05 2012-01-30 Muthiah Manoharan Lipid compositions
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
PT2673296T (pt) 2011-02-07 2019-01-31 Cerenis Therapeutics Holding Sa Complexos de lipoproteínas e sua fabricação e utilização
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
CA2921162A1 (en) * 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
WO2018077159A1 (zh) * 2016-10-27 2018-05-03 中国科学院微生物研究所 氨基酸衰减子的改造方法及其在生产中的应用
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
IL297336A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20230079132A (ko) 2020-10-01 2023-06-05 아비오닉스 파마 에스에이 안질환을 치료하는 데 사용하기 위한 지질 결합 단백질-기반 복합체를 포함하는 조성물
AU2022258815A1 (en) 2021-04-15 2023-10-19 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
KR20240167701A (ko) 2022-04-06 2024-11-27 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 안질환을 치료하는 방법
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250352613A1 (en) 2022-06-10 2025-11-20 Stanislas FAGUER Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
AU6522486A (en) 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
WO1988003175A1 (en) * 1986-10-29 1988-05-05 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii, apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
IE62422B1 (en) 1995-02-08
PT87562B (pt) 1992-09-30
EG19101A (en) 1994-09-29
UA19765A (uk) 1997-12-25
CN1031892C (zh) 1996-05-29
NZ224808A (en) 1990-01-29
FI882456L (fi) 1988-11-29
PT87562A (pt) 1989-05-31
NO882341L (no) 1988-11-29
DE3880739D1 (de) 1993-06-09
JPS6416589A (en) 1989-01-20
JP2634193B2 (ja) 1997-07-23
IE881597L (en) 1988-11-28
DK289688D0 (da) 1988-05-27
US5059528A (en) 1991-10-22
SU1834904A3 (ru) 1993-08-15
HUT47153A (en) 1989-01-30
CZ283648B6 (cs) 1998-05-13
PL158064B1 (pl) 1992-07-31
ATE89006T1 (de) 1993-05-15
CA1323851C (en) 1993-11-02
HK137794A (en) 1994-12-16
CZ363888A3 (cs) 1998-02-18
IL86480A (en) 1992-08-18
NO882341D0 (no) 1988-05-27
CY1809A (en) 1995-10-20
HU204562B (en) 1992-01-28
LTIP828A (en) 1995-02-27
KR880014110A (ko) 1988-12-22
FI882456A0 (fi) 1988-05-25
FI100056B (fi) 1997-09-15
EP0293357A1 (fr) 1988-11-30
KR970000808B1 (en) 1997-01-20
NO179253C (no) 1996-09-04
NO179253B (no) 1996-05-28
AU1672388A (en) 1988-12-01
SK363888A3 (en) 1998-07-08
RU2009198C1 (ru) 1994-03-15
PL272698A1 (en) 1989-03-06
AU615654B2 (en) 1991-10-10
GB8712540D0 (en) 1987-07-01
ZA883824B (en) 1989-02-22
SG131594G (en) 1995-01-13
SK279166B6 (sk) 1998-07-08
LT3600B (en) 1995-12-27
DK175686B1 (da) 2005-01-17
DD291093A5 (de) 1991-06-20
CN88103118A (zh) 1988-12-14
IL86480A0 (en) 1988-11-15
DK289688A (da) 1988-11-29
DE3880739T2 (de) 1993-08-19
LV5288A3 (lv) 1993-10-10
EP0293357B1 (fr) 1993-05-05

Similar Documents

Publication Publication Date Title
DK289688A (da) Ekspression af proapolipoprotein a-i.
CL2004001483A1 (es) Procedimiento para producir una celula vegetal y un cultivo de estas, que son resistentes o tolerantes a un herbicida que inhibe a la glutamina sintetasa mediante la introduccion de un gen que codifica una acetil-transferasa; metodo para producir una
ES2097878T3 (es) Fijacion de p53 sobre el adn mediante una secuencia especifica.
ES2153037T3 (es) Lacasas purificadas de scytalidium y acidos nucleicos que las codifican.
ES2054638T3 (es) Gen codificante de los factores humanos de estimulacion colonial.
MX9205985A (es) Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen.
ES2054701T3 (es) Clonacion y expresion de dna conteniendo el codigo de la toxina bordetella pertussis.
ES8603579A1 (es) Un procedimiento para producir un vector de transferencia de adn.
ES2069742T3 (es) Proteina de la capsida del calicivirus felino y secuencia nucleotida.
DK0719328T3 (da) Genet GRB 3-3, varianter deraf og anvendelse deraf
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.
SV1994000029A (es) Toxina contra arañas insecticidamente eficaz ol 4797
ES2123641T3 (es) Secuencias de acidos nucleicos que codifican o que son complementarias a secuencias de acidos nucleicos que codifican para el receptor de la interleucina 9.
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
ES2059444T3 (es) Procedimiento para la obtencion de acroleinas alfa,beta-substituidas.
ES2000858A6 (es) Un metodo para producir un vector de expresion bacteriano para la expresion de proteinas de fusion
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
CO4290459A1 (es) Variantes de bpn´ con modificada secuencia de aminoacidos, las composiciones limpiadoras que la comprenden y el gel correspondiente del bpn´ mutante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 293357

Country of ref document: ES